Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing’s Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4)

Background: In a prior Phase III, randomized-withdrawal study, osilodrostat, a potent oral 11β-hydroxylase inhibitor, provided rapid and sustained normalization of mean urinary free cortisol (mUFC) in most patients (pts) with CD. Now, we report efficacy and safety results from another Phase III stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Gadelha, Mônica, Bex, Marie, Feelders, Richard A, Heaney, Anthony P, Auchus, Richard J, Gilis-Januszewska, Aleksandra, Witek, Przemyslaw, Belaya, Zhanna, Liao, Zhihong, Ku, Chih Hao Chen, Carvalho, Davide, Roughton, Michael, Wojna, Judi, Hofstetter, Georg, Pedroncelli, Alberto M, Snyder, Peter J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090763/
http://dx.doi.org/10.1210/jendso/bvab048.1055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090763/
http://dx.doi.org/10.1210/jendso/bvab048.1055

Ejemplares similares